Trials / Conditions / Refractory T Acute Lymphoblastic Leukemia

Refractory T Acute Lymphoblastic Leukemia

7 registered clinical trials studyying Refractory T Acute Lymphoblastic Leukemia — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Tr NCT05320380	Children's Oncology Group	Phase 1 / Phase 2
Withdrawn	STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis NCT05519527	M.D. Anderson Cancer Center	Phase 1
Terminated	Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Ly NCT05032183	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Ly NCT04315324	SWOG Cancer Research Network	Phase 1 / Phase 2
Completed	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105	City of Hope Medical Center	Phase 1
Active Not Recruiting	Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute NCT03808610	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblast NCT03504644	ECOG-ACRIN Cancer Research Group	Phase 1 / Phase 2